Breaking News Instant updates and real-time market news.

AIMT

Aimmune

08:09
11/28/16
11/28
08:09
11/28/16
08:09

Aimmune announces global enrollment completion of phase 3 AR101 PALISADE trial

Aimmune Therapeutics announced it has completed global enrollment of its Phase 3 PALISADE trial of AR101 for the treatment of peanut allergy, with the total randomized to the trial expected to be approximately 540 patients. AR101 is Aimmune's investigational biologic oral immunotherapy for desensitization of patients with peanut allergy. Aimmune continues to expect topline data from PALISADE in 4Q17, followed by regulatory submissions for marketing approval of AR101 in 2018 in both the U.S. and Europe. The company announced completion of North American enrollment in PALISADE in September, ahead of schedule and above target enrollment. Aimmune also announced ARTEMIS, a new dedicated European clinical trial of AR101 in peanut-allergic children and adolescents. ARTEMIS is designed to expand the data available on the efficacy profile of AR101 by exploring a higher level of protection after a shorter treatment period in a broader group of patients than in PALISADE. The primary efficacy endpoint in this new trial will be tolerating a cumulative amount of 2,043 mg of peanut protein in an exit double-blind, placebo-controlled food challenge after approximately nine months of treatment with AR101. ARTEMIS is a randomized, double-blind, placebo-controlled trial in peanut-allergic children and adolescents ages 4-17. The inclusion criteria for the trial will allow for baseline toleration of a cumulative amount not exceeding 144 mg of peanut protein in an entry DBPCFC. Patients will undergo approximately six months of up-dosing and then three months of maintenance therapy at 300 mg of AR101 per day, followed by an exit DBPCFC. Aimmune expects ARTEMIS to enroll between 120 and 160 patients at multiple sites in Europe, beginning in mid-2017.

  • 29

    Nov

  • 01

    Dec

  • 14

    Dec

AIMT Aimmune

06/28/16
PIPR
06/28/16
NO CHANGE
Target $38
PIPR
Overweight
Piper reiterates Overweight on Aimmune after management meetings
After hosting meetings with management, Piper Jaffray analyst Charles Duncan reiterates an Overweight rating on Aimmune Therapeutics (AIMT) with a $38 price target. The stock closed yesterday down 44c to $11.01 and is down over 40% year-to-date. No matter how the Phase II data is dissected, Aimmune's AR101 appears to produce a higher response rate in about 50% less time than DBV Technologies' (DBVT) Viaskin, Duncan tells investors in a research note. He believes investors may be overlooking future potential drivers of competitive advantage for AR101.
08/23/16
PIPR
08/23/16
NO CHANGE
PIPR
Aimmune data positive, says Piper Jaffray
Piper Jaffray analyst Charles Duncan says that a study of Aimmune's OIT in very young children with peanut allergies indicates that it provides "clinically meaningful protection and perhaps even a disease modifying effect." The analyst says that the drug demonstrated "unexpectedly good" tolerability, and he believes that the data indicates that the drug could be differentiated versus the current standard of care. He keeps a $38 price target and Overweight rating on the stock.
09/21/16
PIPR
09/21/16
NO CHANGE
Target $38
PIPR
Overweight
Aimmune enrollment completion a 'big positive,' says Piper Jaffray
Piper Jaffray analyst Charles Duncan calls Aimmune Therapeutics' announcement yesterday that it completed North American enrollment of 350 patients in its Phase III PALISADE trial of AR101 as a "big positive." The faster than expected timelike "speaks to the unmet need in peanut allergy across the differentiated, broad patient population enrolled in PALISADE, Duncan tells investors in a research note. The analyst reiterates an Overweight rating on the shares with a $38 price target.
09/26/16
JMPS
09/26/16
INITIATION
Target $30
JMPS
Outperform
Aimmune initiated with an Outperform at JMP Securities
JMP Securities analyst Liisa Bayko initiated Aimmune with an Outperform and a $30 price target. The analyst is confident that AR101 Phase 3 data will show meaningful desensitization to peanuts in allergic children and adults and we will be paying close attention to safety and any discontinuations and projects $1.4B in sales by 2028.

TODAY'S FREE FLY STORIES

TIF

Tiffany

$92.31

0.52 (0.57%)

06:38
06/27/17
06/27
06:38
06/27/17
06:38
Recommendations
Tiffany analyst commentary  »

Tiffany added to US 1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$32.50

0.77 (2.43%)

06:36
06/27/17
06/27
06:36
06/27/17
06:36
Hot Stocks
Micron exploring sale of discontinued Lexar business »

Micron Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 29

    Aug

MON

Monsanto

$117.80

0.78 (0.67%)

06:33
06/27/17
06/27
06:33
06/27/17
06:33
Downgrade
Monsanto rating change  »

Monsanto downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

FMSA

Fairmount Santrol

$3.68

-0.05 (-1.34%)

06:32
06/27/17
06/27
06:32
06/27/17
06:32
Downgrade
Fairmount Santrol rating change  »

Fairmount Santrol…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGO

Assured Guaranty

$41.55

0.9 (2.21%)

06:32
06/27/17
06/27
06:32
06/27/17
06:32
Hot Stocks
S&P affirms Assured Guaranty's AA financial strength ratings with stable outlook »

Assured Guaranty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FET

Forum Energy

06:32
06/27/17
06/27
06:32
06/27/17
06:32
Downgrade
Forum Energy rating change  »

Forum Energy downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLB

Schlumberger

$65.89

-0.04 (-0.06%)

06:32
06/27/17
06/27
06:32
06/27/17
06:32
Downgrade
Schlumberger rating change  »

Schlumberger downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

HP

Helmerich & Payne

$53.16

0.42 (0.80%)

06:32
06/27/17
06/27
06:32
06/27/17
06:32
Downgrade
Helmerich & Payne rating change  »

Helmerich & Payne…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPN

Superior Energy

$9.78

0.04 (0.41%)

06:31
06/27/17
06/27
06:31
06/27/17
06:31
Downgrade
Superior Energy rating change  »

Superior Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBR

Nabors Industries

$7.93

0.06 (0.76%)

06:31
06/27/17
06/27
06:31
06/27/17
06:31
Downgrade
Nabors Industries rating change  »

Nabors Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHI

Baker Hughes

$53.70

-0.29 (-0.54%)

06:31
06/27/17
06/27
06:31
06/27/17
06:31
Downgrade
Baker Hughes rating change  »

Baker Hughes downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PI

Impinj

$59.37

0.58 (0.99%)

06:31
06/27/17
06/27
06:31
06/27/17
06:31
Downgrade
Impinj rating change  »

Impinj downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GEF

Greif

$55.51

-0.1 (-0.18%)

06:29
06/27/17
06/27
06:29
06/27/17
06:29
Conference/Events
Greif to host investor breakfast day »

Investor Breakfast Day to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

UAA

Under Armour

$21.56

0.36 (1.70%)

, UA

Under Armour

$19.92

0.27 (1.37%)

06:27
06/27/17
06/27
06:27
06/27/17
06:27
Recommendations
Under Armour, Under Armour, Kohl's, Nike, adidas analyst commentary  »

Under Armour still…

UAA

Under Armour

$21.56

0.36 (1.70%)

UA

Under Armour

$19.92

0.27 (1.37%)

KSS

Kohl's

$37.52

0.49 (1.32%)

NKE

Nike

$53.28

0.43 (0.81%)

ADDYY

adidas

$94.38

-0.015 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

LYV

Live Nation

$34.86

0.02 (0.06%)

06:20
06/27/17
06/27
06:20
06/27/17
06:20
Recommendations
Live Nation analyst commentary  »

Live Nation price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLT

Hilton

$65.23

-0.17 (-0.26%)

, CHH

Choice Hotels

$66.25

-0.45 (-0.67%)

06:17
06/27/17
06/27
06:17
06/27/17
06:17
Recommendations
Hilton, Choice Hotels, Hyatt, Marriott analyst commentary  »

Deutsche…

HLT

Hilton

$65.23

-0.17 (-0.26%)

CHH

Choice Hotels

$66.25

-0.45 (-0.67%)

H

Hyatt

$58.09

0.39 (0.68%)

MAR

Marriott

$103.93

-0.13 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

GOOGL

Alphabet Class A

$972.09

-14 (-1.42%)

06:14
06/27/17
06/27
06:14
06/27/17
06:14
Technical Analysis
Technical View: Alphabet Class A falls after EU fine, potential bearish pattern »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSUR

OraSure

$15.72

0.17 (1.09%)

06:10
06/27/17
06/27
06:10
06/27/17
06:10
Hot Stocks
OraSure's HIV self-test supported by Gates Foundation for accelerated adoption »

OraSure entered a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

BABA

Alibaba

$142.73

-0.28 (-0.20%)

06:09
06/27/17
06/27
06:09
06/27/17
06:09
Initiation
Alibaba initiated  »

Alibaba resumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

RDWR

Radware

$17.94

-0.04 (-0.22%)

06:06
06/27/17
06/27
06:06
06/27/17
06:06
Hot Stocks
Radware granted ISO27017 and ISO27018 cloud services certifications »

Radware has achieved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jul

  • 13

    Jul

GRPN

Groupon

$3.45

-0.02 (-0.58%)

06:06
06/27/17
06/27
06:06
06/27/17
06:06
Recommendations
Groupon analyst commentary  »

Groupon trading well…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDS

GDS Holdings

$8.83

-0.22 (-2.43%)

, BABA

Alibaba

$142.73

-0.28 (-0.20%)

06:05
06/27/17
06/27
06:05
06/27/17
06:05
Hot Stocks
GDS Holdings announces new order from Alibaba for Beijing 3 data center »

GDS Holdings (GDS)…

GDS

GDS Holdings

$8.83

-0.22 (-2.43%)

BABA

Alibaba

$142.73

-0.28 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

MCK

McKesson

$167.61

0.65 (0.39%)

06:04
06/27/17
06/27
06:04
06/27/17
06:04
Conference/Events
McKesson to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 26

    Jul

  • 30

    Jul

INFO

IHS Markit

$46.40

-0.15 (-0.32%)

06:04
06/27/17
06/27
06:04
06/27/17
06:04
Earnings
IHS Markit sees FY17 adjusted EPS $2.02-$2.08, consensus $2.06 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

UCBI

United Community Banks

$26.70

0.22 (0.83%)

, FOFN

Four Oaks Fincorp

$15.18

0.4 (2.71%)

06:03
06/27/17
06/27
06:03
06/27/17
06:03
Hot Stocks
United Community, Banks Four Oaks Fincorp announce merger agreement »

Community Banks (UCBI)…

UCBI

United Community Banks

$26.70

0.22 (0.83%)

FOFN

Four Oaks Fincorp

$15.18

0.4 (2.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.